Results 271 to 280 of about 49,474 (299)

TDP43 and huntingtin Exon-1 undergo a conformationally specific interaction that strongly alters the fibril formation of both proteins. [PDF]

J Biol Chem
George G, Ajayan A, Varkey J, Pandey NK, Chen J, Langen R.   +5 more
europepmc   +1 more source

Analysis of short tandem repeats linked to polyglutamine diseases from whole-genome sequencing reveals intermediate alleles of <i>HTT</i> associated with an early disease onset in <i>C9orf72</i> carriers. [PDF]

Brain Commun
Barbier M, Gareau T, Camuzat A, Guillaud-Bataille M, Boluda S, Clot F, Araktingi L, Borroni B, van der Zee J, Ghidoni R, Bellini S, Galimberti D, Rossi G, Nacmias B, De la Casa-Fages B, Pastor P, French Clinical and Genetic Research Network on FTD/FTD-ALS and PrevDemALS Study Groups , Latouche M, le Guern E, Durr A, Laquerrière A, Moccia R, Seilhean D, Alvarez V, Le Ber I.   +24 more
europepmc   +1 more source

UBL3 Interacts with PolyQ-Expanded Huntingtin Fragments and Modifies Their Intracellular Sorting. [PDF]

Neurol Int
Oyama S, Zhang H, Ferdous R, Tomochika Y, Chen B, Jiang S, Islam MS, Hasan MM, Zhai Q, Waliullah ASM, Ping Y, Yan J, Mimi MA, Zhang C, Aramaki S, Takanashi Y, Kahyo T, Hashizume Y, Kaneda D, Setou M.   +19 more
europepmc   +1 more source

Huntingtin inclusion bodies have distinct immunophenotypes and ubiquitination profiles in the Huntington's disease human cerebral cortex. [PDF]

Sci Rep
Swanson MEV, Tan AYS, Tippett LJ, Turner CP, Curtis MA, Scotter EL, Lashuel HA, Dragunow M, Faull RLM, Murray HC, Singh-Bains MK.   +10 more
europepmc   +1 more source

Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models. [PDF]

Brain
Sogorb-Gonzalez M, Landles C, Caron NS, Stam A, Osborne G, Hayden MR, Howland D, van Deventer S, Bates GP, Vallès A, Evers M.   +10 more
europepmc   +1 more source

Therapeutic approaches targeting aging and cellular senescence in Huntington's disease. [PDF]

CNS Neurosci Ther
Bhat AA, Moglad E, Afzal M, Thapa R, Almalki WH, Kazmi I, Alzarea SI, Ali H, Pant K, Singh TG, Dureja H, Singh SK, Dua K, Gupta G, Subramaniyan V.   +14 more
europepmc   +1 more source

Phase II trial of intravenous human dental pulp stem cell therapy for Huntington's disease: a randomized, double-blind, placebo-controlled study. [PDF]

Stem Cell Res Ther
Fernandes JMS, Pagani E, Wenceslau CV, Ynoue LH, Ferrara L, Kerkis I.   +5 more
europepmc   +1 more source

In-vitro Neuro-2a cytotoxicity analysis and molecular docking investigation on potential anti-amyloid agents from Adiantum lunulatum. [PDF]

Heliyon
Jerom JP, Jalal A, Sajan AL, Soman R, Nair RH, Narayanan SP.   +5 more
europepmc   +1 more source

The Role of the Glucocorticoid Receptor and Its Phosphorylation in Neurological Disorders. [PDF]

Int J Mol Sci
Gadwala S, Ghosh C.
europepmc   +1 more source